Possible mechanism of dexamethasone therapy for prostate cancer: Suppression of circulating level of interleukin‐6

Glucocorticoids may have favorable effects on prostate cancer patients showing clinical and/or biochemical failure after androgen ablation. The efficacy and mechanisms of dexamethasone therapy as possible alternative endocrine therapy were investigated.

[1]  H. Klocker,et al.  Immunohistochemical localization of interleukin‐6 and its receptor in benign, premalignant and malignant prostate tissue , 2000, The Journal of pathology.

[2]  Y. Horiguchi,et al.  Serum interleukin 6 as a prognostic factor in patients with prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  T. Nishiyama,et al.  Hormone/Antihormone Withdrawal and Dexamethasone for Hormone‐Refractory Prostate Cancer , 1998, International journal of urology : official journal of the Japanese Urological Association.

[4]  K. Akakura,et al.  Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma , 1996, Cancer.

[5]  Y. Furuya,et al.  Incidence and Characteristics of Antiandrogen Withdrawal Syndrome in Prostate Cancer after Treatment with Chlormadinone Acetate , 1998, European Urology.

[6]  D. Tweardy,et al.  Interleukin‐6 induces prostate cancer cell growth accompanied by activation of Stat3 signaling pathway , 2000, The Prostate.

[7]  J. Simons,et al.  Characterization of the role of IL‐6 in the progression of prostate cancer , 1999, The Prostate.

[8]  N Nonomura,et al.  Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. , 2001, Journal of the National Cancer Institute.

[9]  H. Scher,et al.  Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  T. Miki,et al.  Low doses of oral dexamethasone for hormone‐refractory prostate carcinoma , 2000, Cancer.

[11]  G. Murphy,et al.  Circulating levels of interleukin‐6 in patients with hormone refractory prostate cancer , 1999, The Prostate.

[12]  H. Klocker,et al.  Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. , 1998, Cancer research.

[13]  W. Farrar,et al.  Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. , 2000, Cancer research.

[14]  N. Bruchovsky,et al.  Activation of the Androgen Receptor N-terminal Domain by Interleukin-6 via MAPK and STAT3 Signal Transduction Pathways* , 2002, The Journal of Biological Chemistry.

[15]  J. Buckner,et al.  Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone‐refractory metastatic prostate carcinoma , 1995, Cancer.

[16]  R. Oyasu,et al.  Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. , 1997, Cancer research.

[17]  H. Scher,et al.  Hormone-refractory (D3) prostate cancer: refining the concept. , 1995, Urology.